[The results of the MATCH study evidence for advantages of Clopidogrel monotherapy as secondary prophylaxis in cerebrovascular pathology].
A multicenter randomized double-blind placebo-controlled clinical trial The Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) with Transient Ischemic Attack (TIA) or Ischemic Stroke (IS) studied efficacy and safety of a co-medication with acetylsalicylic acid (ASA) and Clopidogrel in comparison with a Clopidogrel monotherapy. It is shown that an addition of ASA to Clopidogrel therapy did not result in significant reduction of the risk of vascular events in patients with cerebrovascular pathology. But comparing to the placebo group, there was a significantly higher frequency of life-threatening bleedings [96 cases (2.6%) versus 49 (1.3%); p < 0.001] and pronounced bleedings [73 cases (1.9%) versus 22 (0.6%); p < 0.001] in the ASA receiving group. Therefore, the results of the MATCH trial demonstrated that ASA did not have any additional benefits while added to Clopidogrel it essentially raised a number of side effects.